Company news
Genfit Sa (EURONEXT:GNFT) news
Genfit Sa news releases on 6ix. Latest, Sep 29, 2026: GENFIT : Reports First-Half 2026 Financial Results and Provides Corporate Update
Press releases & updates
GENFIT : Reports First-Half 2026 Financial Results and Provides Corporate Update
September 29, 2026
GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
September 28, 2026
GENFIT : Résultats financiers du premier semestre 2026 et point sur les activités de la Société
September 27, 2026
GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
September 14, 2026
GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF
September 13, 2026
GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
September 11, 2026
GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
GENFIT annonce sa participation à la H.C. Wainwright 28th Annual Conference
September 9, 2026
GENFIT présente le potentiel commercial à long terme de sa technologie de diagnostic dans la MASH
September 8, 2026
GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026
September 3, 2026
GENFIT organise un événement virtuel avec un leader d’opinion (KOL) consacré au diagnostic de la MASH le 9 septembre 2026
September 2, 2026
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
July 8, 2026
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
July 7, 2026
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
July 2, 2026
GENFIT annonce l’accès à la couverture et le futur remboursement par Medicare aux États-Unis de NASHnext®, une technologie visant à identifier les patients atteints de MASH « à risque »
July 1, 2026
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
June 23, 2026
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
June 15, 2026
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
June 8, 2026
GENFIT Annual General Meeting of June 15, 2026 - Shareholders' letter
June 2, 2026
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
May 25, 2026
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
May 21, 2026
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
May 11, 2026
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
April 20, 2026
GENFIT Announces Publication of the 2025 Universal Registration Document
April 7, 2026
GENFIT : Reports Full-Year 2025 Financial Results and Provides Corporate Update
April 2, 2026
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
April 2, 2026
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
March 9, 2026
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
February 26, 2026
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
February 12, 2026
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
January 13, 2026
GENFIT Announces 2026 Financial Calendar
January 7, 2026
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
January 6, 2026
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
December 10, 2025
GENFIT Announces Appointment of new Chief Medical Officer
November 27, 2025
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
November 20, 2025
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
November 20, 2025
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
November 10, 2025
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
November 10, 2025
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
October 30, 2025
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
October 28, 2025
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
September 22, 2025
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
September 19, 2025
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
June 17, 2025
GENFIT Reports First Quarter 2025 Financial Information
May 22, 2025
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
May 20, 2025
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
May 14, 2025
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents
May 7, 2025
GENFIT to Present Latest ACLF Research at EASL Congress 2025
May 5, 2025
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
April 29, 2025
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
April 28, 2025